SYDNEY, AUSTRALIA: ALS Limited (ASX: ALQ) has announced the acquisition of the remaining 51% stake in Nuvisan Pharma Holding GmbH, a leading European contract research organization (CRO). The acquisition, which includes Nuvisan GmbH and Innovation Campus Berlin (ICB), comes at…
SYDNEY, AUSTRALIA: ALS Limited has today announced that following a comprehensive global search and selection process, the Board has appointed Malcolm Deane as the Managing Director and CEO, effective immediately. ALS Chairman, Bruce Phillips, said, “The Board’s approach of continuous…
SYDNEY, AUSTRALIA: ALS Limited has bought an initial 49% shares in NUVISAN, a pharmaceutical testing business with operations in Germany and France, a news release said. ALS will initially acquire 49% of the equity in NUVISAN for consideration of EUR145…
SYDNEY: ALS Limited announced the acquisition of Investiga, a pharmaceutical testing business with operations in Brazil and the east coast of the USA. Founded in 1993, Investiga is privately owned with 360 employees and generated AUD ~$20m of revenue in…
ALS Limited (ASX: ALQ) is a company headquartered in Brisbane, Australia, which provides testing, inspection, certification, and verification services out of over 370 sites across 65 countries. In 2012, the company was inducted into the Queensland Business Leaders Hall of…